FDA Advisory Committee Votes That Efficacy Results of Cempra’s Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
November 04, 2016 22:40 ET
|
Cempra, Inc.
—FDA PDUFA dates December 27 & 28, 2016— CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing...
Cempra Stock Trading Halted Today; FDA Advisory Committee to Discuss Solithromycin
November 04, 2016 07:05 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces FDA Acceptance of Solithera™ New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia
July 05, 2016 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., July 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference
June 10, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 10, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at the Jefferies 2016 Healthcare Conference
June 02, 2016 08:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., June 02, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Ultra-fast, Meta-genomics Pathogen Detection Software for Diagnosing Infectious Diseases
May 26, 2016 14:22 ET
|
ARUP Laboratories
SALT LAKE CITY, May 26, 2016 (GLOBE NEWSWIRE) -- Scientists at the University of Utah, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer...
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
April 06, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
March 07, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years Cempra to Receive $25.5...
Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
February 24, 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic resistant...
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra’s Oral Solithromycin in Community-Acquired Bacterial Pneumonia
February 05, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone Cempra plans to complete a New Drug Application (NDA) submission to the FDA...